CDK4 Overexpression

CI-VAR-00003190Explore in graph →CIViC 2636

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Alveolar Rhabdomyosarcoma1
CDK4 Overexpression	Palbociclib + RibociclibSubstitutes	Predictive	D	Supports Resistance	3	submitted	EID7138 Analysis of the antiproliferative effects of pharmacologic CDK4/6 inhibitors provided initial evidence of this notion, as lowest CDK4- expressing Rh28 cells showed the highest sensitivity to both LEE0… (full text at CIViC) PMID 25810375 · Olanich et al., 2015 · Open in CIViC	civic
Childhood B-cell Acute Lymphoblastic Leukemia1unmapped disease
CDK4 Overexpression	Dexamethasone + RibociclibCombination	Predictive	D	Supports Sensitivity Response	3	rejected

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.